Treatment concerns for psychiatric symptoms in patients with COVID-19 with or without psychiatric disorders

Many psychiatric patients have been infected with COVID-19, and patients with COVID-19 may develop psychiatric symptoms after treatment with antiviral drugs. Given the tolerability and minimal P450 interactions, antidepressants (i.e., citalopram, escitalopram etc.), antipsychotics (i.e., olanzapine)...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Kai, Zhou, Xiaoqin, Liu, Huanzhong, Hashimoto, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2020
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190394/
https://www.ncbi.nlm.nih.gov/pubmed/32270760
http://dx.doi.org/10.1192/bjp.2020.84
Descripción
Sumario:Many psychiatric patients have been infected with COVID-19, and patients with COVID-19 may develop psychiatric symptoms after treatment with antiviral drugs. Given the tolerability and minimal P450 interactions, antidepressants (i.e., citalopram, escitalopram etc.), antipsychotics (i.e., olanzapine) and valproate can be considered to be safe in combination with antiviral drugs.

Ejemplares similares